JP2003500342A - 哺乳動物の抗腫瘍治療または抗ウイルス治療用に設計された組成物 - Google Patents

哺乳動物の抗腫瘍治療または抗ウイルス治療用に設計された組成物

Info

Publication number
JP2003500342A
JP2003500342A JP2000619390A JP2000619390A JP2003500342A JP 2003500342 A JP2003500342 A JP 2003500342A JP 2000619390 A JP2000619390 A JP 2000619390A JP 2000619390 A JP2000619390 A JP 2000619390A JP 2003500342 A JP2003500342 A JP 2003500342A
Authority
JP
Japan
Prior art keywords
polypeptide
nucleic acid
activity
acid sequence
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000619390A
Other languages
English (en)
Japanese (ja)
Inventor
フィリップ・エルブ
リシャール・ジューン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Publication of JP2003500342A publication Critical patent/JP2003500342A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000619390A 1999-05-25 2000-05-25 哺乳動物の抗腫瘍治療または抗ウイルス治療用に設計された組成物 Pending JP2003500342A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR99/06892 1999-05-25
FR9906892A FR2794025A1 (fr) 1999-05-25 1999-05-25 Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
PCT/FR2000/001422 WO2000071078A2 (fr) 1999-05-25 2000-05-25 Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere

Publications (1)

Publication Number Publication Date
JP2003500342A true JP2003500342A (ja) 2003-01-07

Family

ID=9546225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000619390A Pending JP2003500342A (ja) 1999-05-25 2000-05-25 哺乳動物の抗腫瘍治療または抗ウイルス治療用に設計された組成物

Country Status (7)

Country Link
EP (1) EP1183371A2 (fr)
JP (1) JP2003500342A (fr)
AU (1) AU774391B2 (fr)
CA (1) CA2374941A1 (fr)
FR (1) FR2794025A1 (fr)
HK (1) HK1046426A1 (fr)
WO (1) WO2000071078A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519024A (ja) * 2004-11-08 2008-06-05 トランジェーヌ、ソシエテ、アノニム 哺乳類における抗腫瘍または抗ウイルス治療を行う目的において設計された要素のキット

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1327688A1 (fr) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses avec capacité lytique augmentée
WO2003093303A1 (fr) 2002-05-06 2003-11-13 Board Of Regents, The University Of Texas System Ciblage de proteines pour l'apport de reactifs therapeutiques ou de diagnostic
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
WO2015048312A1 (fr) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2016040892A1 (fr) 2014-09-13 2016-03-17 Novartis Ag Polythérapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07501925A (ja) * 1991-07-03 1995-03-02 アメリカ合衆国 遺伝子移入法および遺伝子移入療法に用いるシトシンデアミナーゼの負の選択系
WO1996016183A1 (fr) * 1994-11-17 1996-05-30 Cayla Genes suicide et associations d'analogues de nucleobases et nucleosides pyrimidiques avec des genes suicide en vue d'une therapie genique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030956A (en) * 1996-10-24 2000-02-29 Boulikas; Teni Combination gene therapy for human cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07501925A (ja) * 1991-07-03 1995-03-02 アメリカ合衆国 遺伝子移入法および遺伝子移入療法に用いるシトシンデアミナーゼの負の選択系
WO1996016183A1 (fr) * 1994-11-17 1996-05-30 Cayla Genes suicide et associations d'analogues de nucleobases et nucleosides pyrimidiques avec des genes suicide en vue d'une therapie genique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6010013349, Ｍｏｌｅｃｕｌａｒ Ｇｅｎｅｔｉｃｓ ａｎｄ Ｍｅｔａｂｏｌｉｓｍ, 1998, Ｖｏｌ．６３, ｐ．１０３−１０９ *
JPN6010013351, Ｈｕｍ Ｇｅｎｅ Ｔｈｅｒ．, 1998, Ｖｏｌ．９， Ｎｏ．５, ｐ．７０７−７１８ *
JPN6010013353, Ｃａｎｃｅｒ Ｌｅｔｔｅｒｓ, 1997, Ｖｏｌ．１１９, ｐ．２３７−２４０ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519024A (ja) * 2004-11-08 2008-06-05 トランジェーヌ、ソシエテ、アノニム 哺乳類における抗腫瘍または抗ウイルス治療を行う目的において設計された要素のキット

Also Published As

Publication number Publication date
HK1046426A1 (zh) 2003-01-10
AU774391B2 (en) 2004-06-24
FR2794025A1 (fr) 2000-12-01
EP1183371A2 (fr) 2002-03-06
AU4931400A (en) 2000-12-12
WO2000071078A2 (fr) 2000-11-30
CA2374941A1 (fr) 2000-11-30
WO2000071078A3 (fr) 2001-04-19

Similar Documents

Publication Publication Date Title
US8211421B2 (en) Mutant having uracil phosphoribosyl transferase activity
US8257692B2 (en) Polypeptide having an improved cytosine deaminase activity
EP1814907B1 (fr) Kit de parties conçues pour la mise en oeuvre d'un traitement antitumoral ou antiviral d'un mammifere
JP2003500342A (ja) 哺乳動物の抗腫瘍治療または抗ウイルス治療用に設計された組成物
AU780074B2 (en) Composition for implementing a cytotoxic, in particular an antitumoral or antiviral, treatment in a mammal
AU2009251215A1 (en) Polypeptide having an improved cytosine deaminase activity

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100323

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100914